Bone Metastases in Gastrointestinal Stromal Tumors


The risk of bone metastases from GISTs, though rare, should be considered during long-term follow-up of patients, especially in those with liver metastases.

The risk of bone metastases from gastrointestinal stromal tumors (GISTs), though rare, should be considered during long-term follow-up of patients, especially in those with liver metastases, according to a recent study published in Oncology Letters that looked at two such cases.

Complete surgical resection is the standard of care for patients with GIST, and the tyrosine kinase inhibitors (TKIs) sunitinib and imatinib are used for patients with recurrence or metastases, or for those with unresectable tumors.

“Imatinib has revolutionized the treatment of advanced GISTs, enabling the long-term survival of patients,” wrote study authors led by Kayo Suzuki, of the department of orthopedic surgery at the University of Toyama in Toyama, Japan. “However, the optimal treatment for bone metastases originating from GIST is yet to be elucidated.”

The most common sites for metastases in patients with GISTs are the peritoneum and liver, according to background information in the article. Cases of bone metastases are rare, with only 12 reported cases in the literature. In 11 of the 12 cases reviewed (92%), patients also had liver metastases. The site of bone metastases most commonly reported was the spine (50%).

“Bone metastases should be completely surgically excised if possible,” wrote the authors. However, none of the spinal lesions from previous cases was resected. “This suggests that metastatic spinal lesions are typically unresectable due to the infiltration of surrounding nervous tissue.”

The first case described in the present study involved a 78-year-old man who presented 5 years after the resection of a GIST with a bone lesion of the femoral neck. The lesion was resected, and the patient was treated with imatinib at 300 mg daily. The patient remains alive at 4 years post-surgery.

The second case involved a 41-year-old man who twice presented with positron emission tomography (PET)/CT-detected bone metastases to the ribs, as well as  liver and renal metastases. Following resection, the patient was treated with imatinib at 400 mg daily. The patient remains alive at 17 years from initial diagnosis.

“Although bone metastases originating from GISTs are rare, the likelihood of identifying metastases in unusual sites is increasing due to the prolonged survival of patients with the tumors and the introduction of imatinib therapy,” wrote the authors in their conclusion. “The risk of bone metastases from GISTs should be considered during long-term follow-up, particularly in the presence of liver metastases.”

Related Videos
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Future developments in the sarcoma space may also involve research on circulating tumor DNA and metabolic therapies, according to Brian Van Tine, MD, PhD.
Current research in the sarcoma space includes the development of treatment options such as T-cell therapies, and combinations such as TKIs/immunotherapy, according to Brian Van Tine, MD, PhD.
Brian Van Tine, MD, PhD, states that sitravatinib appears to be active and well tolerated among patients with dedifferentiated or well-differentiated liposarcoma.
Brian Van Tine, MD, PhD, also discusses how the treatment of desmoid tumors has evolved following data supporting the use of sorafenib in this population.
CAR T-cell therapies and immunotherapy agents may offer up new options and even become standard of care in certain sarcoma subtypes.
There are several novel treatments that may be beneficial in several sarcoma subtypes including CAR T-cell therapies and immune checkpoint inhibitors, according to Sandra P. D’Angelo, MD.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.